Fibroblast growth factor: Difference between revisions
From Proteopedia
Jump to navigationJump to search
Michal Harel (talk | contribs) No edit summary |
Michal Harel (talk | contribs) No edit summary |
||
| Line 12: | Line 12: | ||
* '''FGF10''' has essential role in the growth of fetal prostate <ref>PMID:12941620</ref>.<br /> | * '''FGF10''' has essential role in the growth of fetal prostate <ref>PMID:12941620</ref>.<br /> | ||
* '''FGF12''' is a key regulator of the vascular smooth muscle cell phenotype switch<ref>PMID:27470512</ref>.<br /> | * '''FGF12''' is a key regulator of the vascular smooth muscle cell phenotype switch<ref>PMID:27470512</ref>.<br /> | ||
* '''FGF13''' regulates proliferation and differentiation of the skeletal muscle cells <ref>PMID:26230950</ref>.<br /> | |||
* '''FGF23''' is produced by bone cells and regulates renal phosphate and vitamin D metabolism <ref>PMID:29760049</ref>.<br /> | |||
== Disease == | |||
Mutations in '''FGF20''' are associated with Parkinson's disease<ref>PMID:2823</ref>. | |||
== Relevance == | == Relevance == | ||
'''FGF''' signaling is important in the pathogenesis of a variety of tumor types<ref>PMID:20094046</ref>, angiogenesis<ref>PMID:7542215</ref> and wound healing<ref>PMID:12696985</ref>. '''FGF1''' is a potentially safw candidate for restoring euglycaemia without causing a=overt adverse effects<ref>PMID:28664920</ref>. Overexpression of the high molecular weight isoform of '''FGF2''' in bone results in catabolic activity in joint cartilage and bone that leads to osteoarthropathy<ref>PMID:27732085</ref>. '''FGF12''' could be a therapeutic target for treating restenosis and atherosclerosis. | '''FGF''' signaling is important in the pathogenesis of a variety of tumor types<ref>PMID:20094046</ref>, angiogenesis<ref>PMID:7542215</ref> and wound healing<ref>PMID:12696985</ref>. '''FGF1''' is a potentially safw candidate for restoring euglycaemia without causing a=overt adverse effects<ref>PMID:28664920</ref>. Overexpression of the high molecular weight isoform of '''FGF2''' in bone results in catabolic activity in joint cartilage and bone that leads to osteoarthropathy<ref>PMID:27732085</ref>. '''FGF12''' could be a therapeutic target for treating restenosis and atherosclerosis. '''FGF18''' is overexpressed in ovarian cancer and hence may serve as therapeutic target<ref>PMID:24018557</ref>. '''FGF19''' is overexpressed in lung squamous cell carcinoma and hence may serve as therapeutic target<ref>PMID:28906590</ref>. | ||
== Structural insights == | == Structural insights == | ||
